全文获取类型
收费全文 | 121227篇 |
免费 | 10154篇 |
国内免费 | 5435篇 |
专业分类
耳鼻咽喉 | 648篇 |
儿科学 | 3744篇 |
妇产科学 | 1800篇 |
基础医学 | 28526篇 |
口腔科学 | 1891篇 |
临床医学 | 9163篇 |
内科学 | 21502篇 |
皮肤病学 | 2446篇 |
神经病学 | 7035篇 |
特种医学 | 4235篇 |
外国民族医学 | 37篇 |
外科学 | 9167篇 |
综合类 | 17670篇 |
现状与发展 | 35篇 |
一般理论 | 1篇 |
预防医学 | 5370篇 |
眼科学 | 1670篇 |
药学 | 7579篇 |
13篇 | |
中国医学 | 2746篇 |
肿瘤学 | 11538篇 |
出版年
2023年 | 1290篇 |
2022年 | 1843篇 |
2021年 | 3732篇 |
2020年 | 3242篇 |
2019年 | 4577篇 |
2018年 | 4507篇 |
2017年 | 3861篇 |
2016年 | 3688篇 |
2015年 | 4027篇 |
2014年 | 5866篇 |
2013年 | 7264篇 |
2012年 | 5789篇 |
2011年 | 6920篇 |
2010年 | 5547篇 |
2009年 | 5479篇 |
2008年 | 5792篇 |
2007年 | 6014篇 |
2006年 | 5673篇 |
2005年 | 5137篇 |
2004年 | 4754篇 |
2003年 | 4167篇 |
2002年 | 3545篇 |
2001年 | 3288篇 |
2000年 | 2765篇 |
1999年 | 2343篇 |
1998年 | 2228篇 |
1997年 | 1915篇 |
1996年 | 1492篇 |
1995年 | 1381篇 |
1994年 | 1202篇 |
1993年 | 929篇 |
1992年 | 609篇 |
1991年 | 475篇 |
1990年 | 458篇 |
1989年 | 324篇 |
1988年 | 248篇 |
1987年 | 188篇 |
1985年 | 1326篇 |
1984年 | 2054篇 |
1983年 | 1309篇 |
1982年 | 1439篇 |
1981年 | 1358篇 |
1980年 | 1122篇 |
1979年 | 1025篇 |
1978年 | 901篇 |
1977年 | 767篇 |
1976年 | 869篇 |
1975年 | 607篇 |
1974年 | 544篇 |
1973年 | 580篇 |
排序方式: 共有10000条查询结果,搜索用时 140 毫秒
51.
52.
Marta López-Fauqued Laura Campora Frédérique Delannois Mohamed El Idrissi Lidia Oostvogels Ferdinandus J. De Looze Javier Diez-Domingo Thomas C. Heineman Himal Lal Janet E. McElhaney Shelly A. McNeil Wilfred Yeo Fernanda Tavares-Da-Silva 《Vaccine》2019,37(18):2482-2493
Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献53.
目的:分析组蛋白去乙酰化酶抑制剂TSA处理前后,食管癌细胞株EC109中差异表达的非编码RNA(ncRNA)和mRNA表达谱,初步预测与TSA作用相关的ncRNA和mRNA。方法:采用MTT、细胞周期等方法检测TSA的效应;运用应用芯片技术分别检测TSA处理前后EC109细胞中ncRNA和mRNA表达谱变化,并对差异ncRNA和mRNA表达谱进行整合分析。结果:TSA以剂量时间依赖方式抑制细胞增殖,细胞周期阻滞和凋亡的发生。芯片检测共发现461个ncRNA和758个mRNA显著性差异表达,生物信息学分析显示差异涉及红比霉素、阿霉素代谢过程、氧化还原、核小体的装配、染色质结构组织和端粒的结构组织等。通过数据库分析预测及整合分析,得到了361个ncRNA-mRNA靶基因对。结论:差异表达的ncRNA和mRNA对TSA的生物学效应密切关联,为进一步研究基因功能及其在肿瘤中的生物学意义奠定基础。 相似文献
54.
《Clinical lung cancer》2020,21(2):177-185
BackgroundLittle is known about the difference between black and non-black patients with epidermal growth factor receptor (EGFR)-mutated non–small-cell lung cancer (NSCLC), particularly regarding survival. We thus characterized the EGFR expression profile, clinical characteristics, and survival outcome in these patients.Patient and MethodsWe reviewed the cancer registry and patient charts at a New York-Bronx network (n = 2773) treating a large population of minority patients, for non-squamous NSCLC (n = 1986) diagnosed between 2009 and 2015. Survival was adjusted for smoking, gender, age, weight, and stage.ResultsThe EGFR mutation rate was 15% (98/652) in tested patients (black, 14%; non-black, 16%). There was no significant difference between the 2 cohorts with respect to age at diagnosis, gender, presenting stages, and socioeconomic status. On the other hand, weight was noted to be heavier in black patients with EGFR-mutated NSCLC than their non-black counterparts (P = .012). After adjusting for gender, age, smoking status, weight, and stage, the multivariate analysis revealed no racial disparity in survival among patients with wild-type EGFR (P = .774); However, among patients with EGFR-mutated NSCLC, black patients had shorter survival in comparison with non-black patients (P = .001), with 2-year survival rates being 33% versus 61%, respectively. Such shorter survival was also observed among EGFR-inhibitor treated patients with common EGFR mutations (P = .040).ConclusionsTo our knowledge, this is the first report of inferior survival among black patients with NSCLC with EGFR mutations, relative to non-black patients. The survival disparities suggest the need of more tailored management for this patient population. 相似文献
55.
56.
《Clinical lung cancer》2020,21(6):534-544
BackgroundReliable prediction of progression patterns and failure sites for patients with stage IV lung adenocarcinoma is valuable for physicians to deliver personalized tyrosine kinase inhibitor (TKI) treatment.Patients and MethodsWe retrospectively enrolled 266 patients who had stage IV lung adenocarcinoma and received first-line TKI treatment from 2013 to 2017 in Shanghai Chest Hospital. The clinical characteristics at initial diagnosis, progression patterns, and failure sites were analyzed with the attempt to identify some predictive factors for progression patterns and failure sites.ResultsAmong all patients, 62.4% developed systemic progression, and 37.6% developed oligoprogression. Both cohorts had a median progression-free survival (PFS) of 9 months. The percentage of patients who developed original and distant failure was 39.1% and 60.9%, respectively. Patients with oligometastasis at initial diagnosis were more prone to develop oligoprogression (odds ratio [OR], 4.370; 95% confidence interval [CI], 1.881-10.151; P = .001), whereas pulmonary metastasis was negatively correlated with oligoprogression (OR, 0.567; 95% CI, 0.330-0.974; P = .04). Both oligometastasis diagnosis (OR, 2.959; 95% CI, 1.347-6.500; P = .007) and the maximum diameter of the primary lung lesion (threshold 3.25 cm: OR, 3.646; 95% CI, 2.041-6.515; P = .0001) were strong predictive factors for original failures. Osseous metastasis at initial diagnosis might be an indication for distant failure (OR, 0.536; 95% CI, 0.316-0.909; P = .021).ConclusionOver one-half of patients with stage IV lung adenocarcinoma receiving first-line TKI treatment developed systemic progression and distant failure. Metastasis patterns at initial diagnosis was the most important predictive factor for progression patterns and failure sites. The maximum diameter of the primary lung lesion and evidence of osseous metastasis were also found to be significant indicative factors for failure sites. 相似文献
57.
58.
《The Journal of emergency medicine》2020,58(5):785-796
BackgroundBacteremia causes a major worldwide burden, in terms of financial and productivity costs, as well the morbidity and mortality it can ultimately cause. Proper treatment of bacteremia is a challenge because of the species-dependent response to antibiotics. The T2Bacteria Panel is a U.S. Food and Drug Administration–cleared and culture-independent assay for detection of bacteremia, including common ESKAPE pathogens—Escherichia coli, Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, and Pseudomonas aeruginosa—and provides species identification in as little as 3.6 h directly from blood.ObjectiveOur aim was to evaluate the T2Bacteria assay performance and potential to affect patient care in the emergency department (ED).MethodsED patients from a Louisiana and Florida center were enrolled as part of the T2Bacteria Panel clinical study, which was prospective and noninterventional. Blood samples for blood culture (BC) and T2Bacteria were matched in time and anatomic location.ResultsData from 137 ED patients were evaluated. Relative to BC, T2Bacteria showed 100% positive percent agreement and 98.4% negative percent agreement. In addition, for species on the T2Bacteria Panel, the T2Bacteria assay detected 25% more positives associated with infection, and on average identified the infectious species 56.6 h faster. The T2Bacteria assay covered 70.5% of all species detected by BC. Finally, relative to actual care, the T2Bacteria assay could have potentially focused therapy in 8 patients, reduced time to a species-directed therapy in 4 patients, and reduced time to effective therapy in 4 patients.ConclusionsIn this ED population, the T2Bacteria assay was a rapid and sensitive detector of bacteremia from common ESKAPE pathogens and showed the theoretical potential to influence subsequent patient therapy, ranging from antibiotic de-escalation to faster time to effective therapy. 相似文献
59.
《Cancer cell》2021,39(11):1497-1518.e11
60.